



# GUJARAT TERCE LABORATORIES LIMITED

GUJARAT TERCE LABORATORIES LTD.

CIN:L24100GJ1985PLC007753

Regd.Office: 122/2, Ravi Estate, Bileshwarpura, Chhatral, Dist. Gandhinagar, Gujarat

Statement of Unaudited standalone Financial Results for the Quarter and Nine Months ended 31st December, 2022

[Rs. In Lakhs except per share detail]

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-12-2022 Un Audited	30-09-2022 Unaudited	31-12-2021 Un Audited	31-12-2022 Un Audited	31-12-2021 Un Audited	31-03-2022 Audited
	1	2	3	4	5	6	7
I.	Revenue from operations	1190.48	1257.57	1074.60	3389.40	3080.92	4013.37
II.	Other income	8.43	10.18	6.97	25.31	21.34	30.60
III.	<b>Total Revenue ( I+II )</b>	<b>1198.91</b>	<b>1267.75</b>	<b>1081.57</b>	<b>3414.71</b>	<b>3102.26</b>	<b>4043.97</b>
IV.	<b>Expenses:</b>						
	a) Cost of Material consumed	107.59	145.06	164.52	323.48	445.84	711.14
	b) Purchase of stock in trade	199.98	324.59	319.91	752.60	793.06	1076.51
	c) Changes in inventories of finished goods, WIP and stock in trade.	111.80	18.50	-100.98	227.07	-160.50	-262.83
	d) Employees benefits expenses.	519.46	496.59	394.02	1496.11	1119.47	1582.89
	e) Finance Costs	13.91	21.72	10.27	55.49	25.47	40.09
	f) Depreciation and amortisation exp.	6.89	6.90	5.59	20.69	15.98	27.59
	g) Other Expenses	239.56	313.29	233.03	786.77	602.33	793.91
	<b>Total Expenses</b>	<b>1199.19</b>	<b>1326.65</b>	<b>1026.36</b>	<b>3662.21</b>	<b>2841.65</b>	<b>3969.30</b>
V	<b>Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV )</b>	<b>-0.28</b>	<b>-58.89</b>	<b>55.21</b>	<b>-247.50</b>	<b>260.61</b>	<b>74.66</b>
VI	Exceptional items.	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/(Loss) before extraordinary items and Tax (V-VI)</b>	<b>-0.28</b>	<b>-58.89</b>	<b>55.21</b>	<b>-247.50</b>	<b>260.61</b>	<b>74.66</b>
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit/(Loss) before Tax ( VII-VIII)</b>	<b>-0.28</b>	<b>-58.89</b>	<b>55.21</b>	<b>-247.50</b>	<b>260.61</b>	<b>74.66</b>
X	<b>Tax Expenses</b>						
	1) Current Tax	0.00	0.00	7.50	0.00	7.50	0.00
	2) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-12.57
XI	<b>Profit/(Loss) for the period from continuing operations (IX-X)</b>	<b>-0.28</b>	<b>-58.89</b>	<b>47.71</b>	<b>-247.50</b>	<b>253.11</b>	<b>87.23</b>
XII	<b>Other Comprehensive Income</b>						
	A. (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	<b>Other Comprehensive Income for the period, net of tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIV	<b>Total Comprehensive Income for the period (XI+XII)</b>	<b>-0.28</b>	<b>-58.89</b>	<b>47.71</b>	<b>-247.50</b>	<b>253.11</b>	<b>87.23</b>
XV	<b>Paid up Equity Capital ( at par value of Rs. 10 each)</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>	<b>742.03</b>
XVI	<b>Earning per equity share</b>						
	a ) Basic	0.00	-0.79	0.64	-3.34	3.41	1.18
	b ) Diluted	0.00	-0.79	0.64	-3.34	3.41	1.18
	(See accompanying notes to the Financial Results)						


**Notes:**

- The above Unaudited financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on January, 31, 2022.
- The Statutory Auditors have carried out the Limited Review of the above financial results of the Company for the quarter and nine month ended on December 31, 2022.
- The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- The Company is operating in single (Pharmaceutical) segment, so above results are for single segment only.
- To facilitate Comparison, figures of previous periods has been regrouped, wherever necessary.

Place: Ahmedabad

Date: 31/01/2023

For, Gujarat Terce Laboratories Limited



Aalap Prajapati

Managing Director & CEO

DIN: 08088327

Regd. Office & Factory : 122/2 Ravi Estate, Bileshwarpura,  
Chhatral, Ta. : Kalol, Dist. : Gandhinagar (Guj.) INDIA.  
Ph.: 02764-233182 • E.mail : gtl.factory@gmail.com  
CIN : L28112GJ1985PLC007753

Admn. Office : D/801 & 802, The First, Behind Keshavbaug Party Plot,  
Near Shivalik High-street, Vastrapur, Ahmedabad-380015 Gujarat.(INDIA) • Ph.: 079-48933701  
E.mail : ho@gujaratterce.com • Web. : www.gujaratterce.com

CIN: L24100GJ1985PLC007753



**Limited Review Report for unaudited standalone quarterly results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.**

To,  
The Board of Directors,  
Gujarat Terce Laboratories Limited  
Gujarat

We have reviewed the accompanying statement of unaudited financial results of Gujarat Terce Laboratories Limited for the quarter ended December 31, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

**Place: Anand**  
**Date: 31/01/2023**

**For, M. A. Shah & Co.**  
**Chartered Accountants**



**CA Parag Patel**  
**(Partner)**  
**Mem. No.: 155916**  
**FRN: 112630W**  
**UDIN: 23155916BGVILB5386**